» Articles » PMID: 37435360

ASXL3 Gene Mutations Inhibit Cell Proliferation and Promote Cell Apoptosis in Mouse Cardiomyocytes by Upregulating LncRNA NONMMUT063967.2

Overview
Specialty Biochemistry
Date 2023 Jul 12
PMID 37435360
Authors
Affiliations
Soon will be listed here.
Abstract

Congenital heart disease (CHD) is a serious condition with unknown etiology. In a recent study, a compound heterozygous mutation (c.3526C > T [p.Arg1176Trp] and c.4643A > G [p.Asp1548Gly]) in the ASXL3 gene was identified, which is associated with CHD. This mutation was overexpressed in HL-1 mouse cardiomyocyte cells, leading to increased cell apoptosis and decreased cell proliferation. However, whether this effect is mediated by long noncoding RNAs (lncRNAs) is yet to be determined. We identified the differences among lncRNA and mRNA profiles in mouse heart tissues using sequencing to explore this issue. We detected HL-1 cell proliferation and apoptosis through CCK8 and flow cytometry. Fgfr2, lncRNA, and Ras/ERK signaling pathway expressions were evaluated using quantitative real time polymerase chain reaction (qRT-PCR) and western blot (WB) assays. We also conducted functional investigations by silencing lncRNA NONMMUT063967.2. The sequencing revealed significant changes in lncRNA and mRNA profiles, with the expression of lncRNA NONMMUT063967.2 being significantly promoted in the ASXL3 gene mutations group (MT) while the expression of Fgfr2 being downregulated. The experiments showed that ASXL3 gene mutations inhibited the proliferation of cardiomyocytes and accelerated cell apoptosis by promoting the expression of lncRNAs (NONMMUT063967.2, NONMMUT063918.2, and NONMMUT063891.2), suppressing the formation of FGFR2 transcripts, and inhibiting the Ras/ERK signaling pathway. The decrease in FGFR2 had the same effect on the Ras/ERK signaling pathway, proliferation, and apoptosis in mouse cardiomyocytes as ASXL3 mutations. Further mechanistic studies revealed that suppression of lncRNA NONMMUT063967.2 and overexpression of FGFR2 reversed the effects of the ASXL3 mutations on the Ras/ERK signaling pathway, proliferation, and apoptosis in mouse cardiomyocytes. Therefore, ASXL3 mutation decreases FGFR2 expression by upregulating lncRNA NONMMUT063967.2, inhibiting cell proliferation and promoting cell apoptosis in mouse cardiomyocytes.

Citing Articles

Cardiomyocyte proliferation and regeneration in congenital heart disease.

Liang J, He X, Wang Y Pediatr Discov. 2024; 2(3).

PMID: 39308981 PMC: 11412308. DOI: 10.1002/pdi3.2501.

References
1.
Fu F, Li R, Lei T, Wang D, Yang X, Han J . Compound heterozygous mutation of the ASXL3 gene causes autosomal recessive congenital heart disease. Hum Genet. 2020; 140(2):333-348. DOI: 10.1007/s00439-020-02200-z. View

2.
Huang C, Wang R, Lu J, He Y, Wu Y, Ma W . MicroRNA-338-3p as a therapeutic target in cardiac fibrosis through FGFR2 suppression. J Clin Lab Anal. 2022; 36(8):e24584. PMC: 9396162. DOI: 10.1002/jcla.24584. View

3.
Parikh C, Greenberg J, McArthur E, Thiessen-Philbrook H, Everett A, Wald R . Incidence of ESKD and Mortality among Children with Congenital Heart Disease after Cardiac Surgery. Clin J Am Soc Nephrol. 2019; 14(10):1450-1457. PMC: 6777584. DOI: 10.2215/CJN.00690119. View

4.
Panni S, Lovering R, Porras P, Orchard S . Non-coding RNA regulatory networks. Biochim Biophys Acta Gene Regul Mech. 2019; 1863(6):194417. DOI: 10.1016/j.bbagrm.2019.194417. View

5.
Xu W, Wu Q, Huang A . Emerging Role of LncRNAs in Autoimmune Lupus. Inflammation. 2022; 45(3):937-948. DOI: 10.1007/s10753-021-01607-8. View